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Abstract
Photoimmunotherapy (PIT) of cancer utilizes tumor-specific monoclonal antibodies conjugat-
ed to a photosensitizer phthalocyanine dye IR700 which becomes cytotoxic upon irradiation
with near infrared light. In this study, we aimed to evaluate the efficacy of PIT on human pan-
creatic cancer cells in vitro and in vivo in an orthotopic nudemouse model. The binding ca-
pacity of anti-CEA antibody to BxPC-3 human pancreatic cancer cells was determined by
FACS analysis. An in vitro cytotoxicity assay was used to determine cell death following treat-
ment with PIT. For in vivo determination of PIT efficacy, nude mice were orthotopically im-
planted with BxPC-3 pancreatic tumors expressing green fluorescent protein (GFP). After
tumor engraftment, the mice were divided into two groups: (1) treatment with anti-CEA-IR700
+ 690 nm laser and (2) treatment with 690 nm laser only. Anti-CEA-IR700 (100 μg) was ad-
ministered to group (1) via tail vein injection 24 hours prior to therapy. Tumors were then sur-
gically exposed and treated with phototherapy at an intensity of 150 mW/cm2 for 30 minutes.
Whole body imaging was done subsequently for 5 weeks using an OV-100 small animal im-
aging system. Anti-CEA-IR700 antibody bound to the BxPC3 cells to a high degree as shown
by FACS analysis. Anti-CEA-IR700 caused extensive cancer cell killing after light activation
compared to control cells in cytotoxicity assays. In the orthotopic models of pancreatic can-
cer, the anti-CEA-IR700 group had significantly smaller tumors than the control after 5 weeks
(p<0.001). There was no significant difference in the body weights of mice in the anti-
CEA-IR700 and control groups indicating that PIT was well tolerated by the mice.
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Introduction
Photoimmunotherapy (PIT) uses tumor specific monoclonal antibodies that are conjugated to
the photosensitizer phthalocyanine dye, IR700, which is cytotoxic upon irradiation with near-
infrared (NIR) light [1–3].
Several monoclonal antibodies (mAbs) have been used with PIT in mouse models of breast
cancer including trastuzumab, a monoclonal antibody (mAb) directed against human epider-
mal growth factor receptor-2 (HER-2), and panitumumab, a monoclonal antibody directed
against human epidermal growth factor receptor-1 (HER-1) [4,5]. Cell death was induced im-
mediately after irradiating mAb-IR700–bound target cells with NIR light. In vivo tumor
shrinkage after irradiation with NIR light was demonstrated in target cells expressing the epi-
dermal growth factor receptor. The mAb-IR700 conjugates were effective when bound to the
cell membrane and produced no phototoxicity when not bound, suggesting a different mecha-
nism for PIT as compared to conventional photodynamic therapies [1].
Pancreatic cancer is a lethal tumor with high rates of local and distant recurrence [6,7]. In
the present study, we used a chimeric monoclonal antibody against the carcinoembryonic anti-
gen (CEA) for PIT, which is often overexpressed in pancreatic cancer and has been previously
utilized by our laboratory for fluorescence-guided surgery and fluorescence laparoscopy
[8–17]. The anti-CEA antibody was conjugated to IR700 and used for PIT treatment of human
pancreatic cancer in orthotopic mouse models as well as pancreatic cancer cells in vitro.
Materials and Methods
Cell Culture
The human pancreatic cancer cell line BxPC-3 was stably transduced to express green fluores-
cent protein (GFP) as previously described [18,19]. Cells were maintained in RPMI 1640 medi-
um supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), penicillin/streptomycin
(Gibco-BRL, Carlsbad, CA), sodium pyruvate (Gibco-BRL), sodium bicarbonate (Cellgro, Ma-
nassas, VA), L-glutamine (Gibco-BRL), and minimal essential medium nonessential amino
acids (Gibco-BRL). All cells were cultured at 37°C in a 5% CO2 incubator.
Determination of CEA antigen expression level
BxPC-3-GFP cells from a 75 cm2 flask were harvested with enzyme-free cell dissociation buffer,
washed once with incubation buffer (PBS + 0.5% FBS + 0.1% sodium azide), and recovered in
incubation buffer at 2 x 106 cells/ml and kept at 4°C. The cells (5 x 105) were incubated with
chimeric anti-CEA antibody (Genara Biosciences LLC, Morgan Hill, CA) (10 μg/ml) in 300 μl
incubation buffer for 1 hour at 4°C, washed three times with PBS and stained with an Alex-
a488-conjugated donkey anti human IgG (H+L) antibody (Jackson Immunoresearch, West
Grove, PA) for 45 minutes, followed by three washes with PBS. A control without anti-CEA
was prepared in parallel. Flow cytometry profiles from the anti-CEA antibody-treated cells and
the untreated cells were established on a Guava EasyCyte Plus flow cytometer (EMDMillipore,
Billerica, MA). The antibody binding capacity for anti-CEA was determined by using reference
beads (Bangs Laboratories, Inc., Fishers, IN) and geometric means according to the
manufacturer’s protocol.
Animals
Athymic nu/nu nude mice (AntiCancer Inc., San Diego, CA), 4–6 weeks old, were used in this
study. Mice were kept in a barrier facility under HEPA filtration. Mice were fed with an auto-
claved laboratory rodent diet. All mouse surgical procedures and imaging were performed with
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the animals anesthetized by intramuscular injection of 50% ketamine, 38% xylazine, and 12%
acepromazine maleate (0.02 ml). Animals received buprenorphine (0.10 mg/kg ip) immediate-
ly prior to surgery and once a day over the next 3 days to ameliorate pain. CO2 inhalation was
used for euthanasia of all animals at 5 weeks after surgery. To ensure death following CO2 as-
phyxiation, cervical dislocation was performed. All animal studies were conducted with an An-
tiCancer, Inc. Institutional Animal Care and Use Committee (IACUC)-protocol specifically
approved for this study and in accordance with the principals and procedures outlined in the
National Institute of Health Guide for the Care and Use of Animals under Assurance Number
A3873–1.
Antibody-Dye Conjugation
A water-soluble silicon-phthalocyanine derivative, IRDye 700DX NHS ester was obtained
from LI-COR Bioscience (Lincoln, NE). of Chimeric anti-CEA antibody (Genara Biosciences
LLC) (2 mg [~ 14 nmol]) at a concentration of 2 mg/ml in 0.1 M Na2HPO4 (pH = 8.6) was in-
cubated for 2 hours at room temperature with IR700dye NHS ester (135 ug, 70 nmol) prepared
in anhydrous DMSO at 5 mmol/L. After the incubation period, the IR700-conjugate was buffer
exchanged and purified with phosphate buffer saline (PBS, pH = 7.1) using Amicon Ultra Cen-
trifugal Filter Units (EMDMillipore Corporation, Billerica, MA). The IR700-mAb conjugate
was repeatedly diluted with 10 ml volumes of PBS and then concentrated using the filter units
until less than 2% of the unconjugated IR700 dye species remained, as determined by size
Fig 1. Staining of BxPC-3 cells with anti-CEA antibody and quantification of binding sites. BxPC-3 cells were treated with anti-CEA antibody and
stained with a fluorochrome conjugated secondary antibody against anti-CEA (red, filled), or control-stained with secondary antibody only (black, open) and
analyzed by flow cytometry. Gating was for the main population (A). The anti-CEA antibody binding capacity, determined with reference beads, was very high
(2,227,000 binding sites per cell) (B).
doi:10.1371/journal.pone.0121989.g001
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exclusion HPLC (SE-HPLC). Analysis of the conjugates by SE-HPLC was performed using an
Agilent 1100 HPLC system fitted with a TSKgel G2000SWxl column (Tosoh Biosciences,
Tokyo, Japan). The SE-HPLC elution buffer was 1X PBS (pH = 7.1) with a flow rate of 1 ml/
min. UV/Vis detection at 280 nm and 690 nm was used to determine the average dye-to-anti-
body ratio (DAR) for each conjugates. With this sample, a purity of 97.6% with 0.5% free dye
and a DAR of 4.1 was achieved.
Tumor implantation
After confluence, BxPC-3-GFP human pancreatic cancer cells (1 x 106) were injected subcuta-
neously into the flanks of nude mice and allowed to engraft and grow over a period of 4–6
weeks. Tumors were then harvested and tumor fragments (1 mm3) from subcutaneous tumors
were sutured to the tail of the pancreas using 8–0 nylon surgical sutures (Ethilon; Ethicon Inc.,
Somerville, NJ). On completion, the tail of the pancreas was returned to the abdomen, and the
incision was closed in one layer using 6–0 nylon surgical sutures (Ethilon) [20,21]. The tumor
fragments were allowed to grow over a period of 2 weeks.
Cytotoxicity studies
BxPC-3 cells were seeded in white-wall 96-well plates (4,000/well) and allowed to attach over-
night. Cells were incubated with the antibody conjugate, anti-CEA-IR700, (dye-antibody ratio
of 5.1) at 10 mg/ml for 2 hours at 37°C. Four wells at a time were subjected to treatment with
Fig 2. Light-induced cell death by cell-bound anti-CEA-IR700. BxPC-3 cells were incubated with anti-CEA-IR700 conjugate (10 μg/ml). Rapid cell killing
was observed with a dose of 32 J/cm2 of 690 nm near-infrared light (blue circles), whereas only little cell killing occurred without illumination (green triangles).
Death in light-treated cells in the absence of anti-CEA-IR700 was negligible (data not shown).
doi:10.1371/journal.pone.0121989.g002
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690 nm light from an LED (Marubeni Corporation, Tokyo, Japan) at a power density of
50 mW/cm2 that was calibrated with a power meter equipped with a photodiode power sensor
(Thorlabs Inc., Newton, NJ). After light treatment, the antibody solution was replaced with
complete RPMI 1640 medium, containing CytoTox Green (Promega, Madison, WI) to moni-
tor cell killing.
Photoimmunotherapy in vivo
Anti-CEA antibody (100μg) (Genara Biosciences LLC, Morgan Hill, CA) conjugated to
IR700DX reconstituted to 100 μl was injected via tail vein in the treatment group 24 hours
prior to intervention, while the control group had 100 μl of PBS similarly injected 24 hours
prior to injection. Each group consisted of 10 mice with orthotopic BxPC-3-GFP tumors.
After 24 hours, the pancreatic tumors in all 10 mice in the treatment group were exposed via
a left lateral incision and imaged to detect both the GFP signal and the 700 nm signal. All the
mice were subsequently subjected to photoimmunotherapy by exposing the tumor to a 690 nm
laser at 150 mW/cm2 for 30 minutes for a total of 270 J/cm2. The surrounding normal tissues
were protected with aluminum foil during PIT. Mice were imaged at the time of therapy and
weekly thereafter with tumor exposed to evaluate response to therapy. After 5 weeks the mice
were sacrificed, at which point they were imaged and had their tumors resected and weighed.
Fig 3. Experimental protocol for in vivo PIT. Two weeks after orthotopic implantation of BxPC-3-GFP tumors, engraftment was ensured and mice were
divided into 2 groups with the treatment group receiving anti-CEA-IR700 conjugate (100 μg) and the 2nd group receiving an injection with PBS. Mice were
serially imaged weekly over the course of 5 weeks to measure orthotopic tumor growth.
doi:10.1371/journal.pone.0121989.g003
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Animal Imaging
Mice were imaged weekly using the Olympus OV100 small animal imaging system (Olympus
Corp. Tokyo, Japan), containing an MT-20 light source (Olympus Biosystems Planegg, Ger-
many) and DP70 CCD camera (Olympus Corp. Tokyo, Japan) [22]. All images were analyzed
using Image-J (National Institute of Health Bethesda, MD) and were processed with the use of
Photoshop elements-11 (Adobe Systems Inc. San Jose, CA).
Tumor size determination
The mice in both groups had weekly laparotomy to expose the pancreatic tumors via a left lat-
eral incision. Tumors were imaged with the OV-100 by GFP expression. Tumor size was as-
sessed using Image-J software (National Institutes of Health, Bethesda, Maryland).
Statistical Analysis
All statistical analysis was done using SPSS software version 21 (IBM, Armonk, NY). For pair-
wise comparisons, quantitative variables were calculated using the paired-samples Student’s
t-test and confirmed with the Wilcoxon rank-sum test. A p-value0.05 was considered signifi-
cant. 95% confidence intervals obtained on analysis of the data were configured into the error
bars of the appropriate figures and graphs.
Fig 4. GFP weekly imaging of pancreatic tumors.Mice had their tumors exposed via a left lateral incision and imaged with the OV-100. Maximal effect of
PIT was noted one week after initiation of therapy.
doi:10.1371/journal.pone.0121989.g004
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Results and Discussion
Anti-CEA-IR700 binds to CEA-expressing pancreatic cancer cells in vitro
and causes extensive cell death after light activation compared to control
The anti-CEA antibody binding capacity to BxPC3 human pancreatic cancer cells was
2,227,000 binding sites per cell by FACS analysis (Fig. 1). Cells were incubated with anti-
CEA-IR700 and treated with 690 nm light. At the end of the incubation, there was 100% cell
death in the anti-CEA IR700 + 690 nm light group compared to a negligible amount of cell
death in the no-690 nm light group (Fig. 2). Death of 690 nm light-treated cells in absence of
Anti-CEA-IR700 was negligible (data not shown).
PIT results in a significant reduction in tumor size and weight in an
orthotopic mouse model of pancreatic cancer
Two weeks after orthotopic implantation of BxPC-3-GFP tumors, engraftment was ensured
and mice were divided into 2 groups with the treatment group receiving anti-CEA-IR700 con-
jugate (100 μg) and the control group receiving PBS (Fig. 3). Tumor size was assessed on a
weekly basis to evaluate response to therapy and overall differences in progression. In the con-
trol group there was an initial exponential increase in tumor size that began to plateau at week
4 achieving a maximum average of 390.7 mm2 (95% CI [347.7, 433.7]). In contrast, in the treat-
ment group there was an initial decrease in tumor size from baseline with a maximal response
seen at week 1 (Figs. 4 and 5) with an average size of 6.65mm2 (95% CI [1.75, 11.5]). Over the
Fig 5. Graphical representation of tumor size over 5 weeks. Tumor sizes were determined using image-J software (National Institutes of Health,
Bethesda, Maryland).
doi:10.1371/journal.pone.0121989.g005
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course of the experiment, the tumor began to regrow, reaching a maximum average of 29.5
mm2 (95% CI [16.5, 42.5]) at 5 weeks post-treatment. The difference in tumor size between the
control and the treatment groups was significant (p<0.001).
At the termination of the experiment at week 5, the tumors in both groups were excised and
weighed. Complete excision was confirmed with the OV-100 by GFP fluorescence. The average
tumor weight was 3872 mg (95% CI [3213, 4531]) for the control group and 239.6 mg (95% CI
[81, 397]) for the treatment group (p<0.001) (Figs. 6 and 7).
The average body weights of the mice after one week of treatment were 26.3 grams (95% CI
[25.1, 27.4]) for the PIT group and 25.1 grams for the control group (95% CI [24, 26.2]) which
was not statistically different (p = 0.23). The average body weights of the mice 5 weeks after
treatment were 29.2 grams (95% CI [28, 30.5]) for the PIT group and 28.7 grams (95% CI
[27, 30.3]) for the control group which was also not statistically different (p = 0.64), indicating
that PIT was well tolerated by the mice.
Despite the anti-tumor effects of PIT, there was however a 100% recurrence rate. Previous
studies have shown that the rate and amount of tumor cell destruction is dependent on both
the conjugate dose and the light dose, the product of which results in the same cytotoxic effect
regardless of the method of light delivery (continuous or intermittent) [2,23]. In this regard,
further investigation is needed to assess how dosing of the anti-CEA-IR700 complex and vary-
ing the mode and amount of energy delivery could increase efficacy.
Fig 6. Graphical representation of tumor weights. A significant difference was noted with average tumor weights after tumor resection. A significant
difference in tumor weight was noted between the treatment and control groups (p<0.001).
doi:10.1371/journal.pone.0121989.g006
Photoimmunotherapy for Pancreatic Cancer
PLOS ONE | DOI:10.1371/journal.pone.0121989 March 23, 2015 8 / 11
A single round of treatment was employed in the present report as proof of principle in an
orthotopic model of pancreatic cancer. Multiple rounds of PIT will be performed in future experi-
ments. Repeated rounds of therapy have been shown to increase the efficacy of PIT [4]. It is ex-
pected that repeated rounds of PIT would reduce the recurrence rate. Repeated rounds of PIT
should be feasible due to the low toxicity observed. PIT should be able to add the efficacy of sur-
gery and radiation therapy when used in combination with these therapies. This will be tested in
orthotopic models, including immunocompetent mice, and in experimental high metastatic mod-
els, as well as in patient-derived orthotopic xenograft (PDOX) models in future experiments.
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